State of Alaska Department of Revenue Increases Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

State of Alaska Department of Revenue increased its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 387.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 33,173 shares of the specialty pharmaceutical company’s stock after buying an additional 26,370 shares during the period. State of Alaska Department of Revenue owned about 0.05% of Jazz Pharmaceuticals worth $3,695,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. DekaBank Deutsche Girozentrale increased its stake in shares of Jazz Pharmaceuticals by 37.3% during the third quarter. DekaBank Deutsche Girozentrale now owns 115,130 shares of the specialty pharmaceutical company’s stock valued at $12,641,000 after buying an additional 31,283 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Jazz Pharmaceuticals by 15.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,476 shares of the specialty pharmaceutical company’s stock valued at $275,000 after buying an additional 325 shares during the period. Warther Private Wealth LLC purchased a new position in shares of Jazz Pharmaceuticals during the third quarter valued at $3,700,000. Tectonic Advisors LLC increased its stake in shares of Jazz Pharmaceuticals by 6.3% during the third quarter. Tectonic Advisors LLC now owns 3,891 shares of the specialty pharmaceutical company’s stock valued at $433,000 after buying an additional 232 shares during the period. Finally, Hennion & Walsh Asset Management Inc. increased its stake in shares of Jazz Pharmaceuticals by 7.2% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 31,562 shares of the specialty pharmaceutical company’s stock valued at $3,516,000 after buying an additional 2,115 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on JAZZ shares. Royal Bank of Canada raised their price objective on Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an “outperform” rating in a research report on Wednesday, October 23rd. StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. Needham & Company LLC reaffirmed a “buy” rating and set a $205.00 price objective on shares of Jazz Pharmaceuticals in a research report on Tuesday, September 10th. HC Wainwright reaffirmed a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, August 1st. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $140.00 price target on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. Three analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $173.43.

Insider Activity at Jazz Pharmaceuticals

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the sale, the senior vice president now directly owns 14,531 shares in the company, valued at $1,573,707.30. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.20% of the stock is owned by company insiders.

Jazz Pharmaceuticals Stock Up 1.1 %

Shares of JAZZ stock opened at $113.18 on Thursday. The stock has a 50 day moving average of $110.86 and a 200 day moving average of $109.54. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 1.36. The stock has a market cap of $7.14 billion, a P/E ratio of 23.34, a P/E/G ratio of 1.41 and a beta of 0.57. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $134.48.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share for the quarter, beating the consensus estimate of $3.80 by $0.87. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion. Jazz Pharmaceuticals had a return on equity of 28.65% and a net margin of 10.10%. As a group, sell-side analysts expect that Jazz Pharmaceuticals plc will post 16.06 EPS for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.